Ponaxen 15 mg is a tyrosine kinase inhibitor (TKI) designed for the treatment of patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), particularly in cases where resistance or intolerance to prior therapy has occurred. Ponaxen targets ABL tyrosine kinase, including the T315I mutation, which is resistant to many other TKIs. In addition, Ponaxen inhibits multiple kinases such as VEGFR, PDGFR, FGFR, EPH receptors, SRC family kinases, KIT, RET, TIE2, and FLT3, helping to reduce the proliferation of malignant cells.

Ponaxen has demonstrated preclinical efficacy in reducing tumor size in animal models expressing native or mutant BCR-ABL and is indicated for patients under careful medical supervision with ongoing monitoring of hematologic, cardiovascular, and hepatic parameters.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Ponaxen 15 mg is indicated for:

• Chronic myeloid leukemia (CML), including patients with T315I mutation

• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) resistant or intolerant to other tyrosine kinase inhibitors

• Patients requiring targeted therapy for malignancies with aberrant kinase activity sensitive to Ponatinib

Pharmacology

Ponaxen 15 mg inhibits multiple kinases involved in tumor growth and angiogenesis, including ABL, VEGFR, PDGFR, FGFR, and SRC family kinases. By blocking these pathways, Ponaxen reduces cell proliferation, stabilizes disease, and prevents disease progression in resistant leukemia.

Dosage and Administration

• Starting Dose: 45 mg once daily

• Dose Reduction: May be reduced to 15 mg for chronic phase CML patients achieving a major cytogenetic response

• Administration: Oral, once daily; continue as long as clinical benefit persists without unacceptable toxicity

• Monitoring: Cardiovascular status, blood counts, liver function tests, and BCR-ABL transcript levels

• Special Populations:

  • Elderly: More likely to experience adverse reactions; monitor closely

  • Hepatic impairment: Caution advised

  • Renal impairment: Use with caution if creatinine clearance <50 mL/min

  • Pediatric (<18 years): Safety and efficacy not established

Drug Interactions

• CYP3A4 inhibitors: Reduce starting dose to 30 mg (e.g., ketoconazole, itraconazole, clarithromycin, grapefruit juice)

• CYP3A4 inducers: Avoid co-administration (e.g., rifampicin, carbamazepine, St. John’s Wort)

• Monitor for underexposure or toxicity when used with interacting drugs

Contraindications

• Hypersensitivity to Ponatinib or any excipients

Side Effects

Common serious adverse reactions (>2%) include:

• Cardiovascular: Myocardial infarction, atrial fibrillation, arterial occlusive events, heart failure

• Hematologic: Thrombocytopenia, neutropenia, anemia, febrile neutropenia, platelet count decreased

• Gastrointestinal: Pancreatitis, abdominal pain

• Other: Pneumonia, pyrexia, urinary tract infection, sepsis, cellulitis, elevated lipase

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions & Warnings

• Myelosuppression: Monitor complete blood counts every 2 weeks for the first 3 months, then monthly

• Arterial Occlusions: Monitor for thromboembolic events; interrupt therapy if needed

• Hypertension: Manage and monitor at each clinic visit; interrupt therapy if uncontrolled

• Hepatotoxicity: Monitor liver function tests prior to initiation and periodically

• Severe Hemorrhage: Interrupt therapy and evaluate immediately

• Hepatitis B reactivation: Test patients before starting; monitor carriers during and after treatment

Pregnancy and Lactation

• Pregnancy: Use only if clearly necessary; animal studies indicate reproductive toxicity

• Breastfeeding: Discontinue due to potential risk

• Fertility: Effects observed on female fertility in animal studies; relevance to humans unknown

Overdose

• Stop Ponaxen immediately

• Provide supportive treatment and monitoring

• Reported overdoses have included QT prolongation, atrial fibrillation, pneumonia, and systemic complications

Storage Conditions

• Store in a cool, dry place below 30°C

• Avoid exposure above 40°C

• Keep out of reach of children